☰

Careen K. Tang - Publications

Affiliations: 
Tumor Biology Georgetown University, Washington, DC 
Area:
Cell Biology, Molecular Biology, Oncology
Tree Info Grants Similar researchers PubMed Report error

21 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2013 Chang KY, Tsai SY, Chen SH, Tsou HH, Yen CJ, Liu KJ, Fang HL, Wu HC, Chuang BF, Chou SW, Tang CK, Liu SY, Lu PJ, Yen CY, Chang JY. Dissecting the EGFR-PI3K-AKT pathway in oral cancer highlights the role of the EGFR variant III and its clinical relevance. Journal of Biomedical Science. 20: 43. PMID 23806066 DOI: 10.1186/1423-0127-20-43  0.38
2013 Chang K, Tsai S, Chen S, Tsou H, Yen C, Tang CK, Yen C, Chang J. Abstract 2390: EGFR variant III act as the major determinant factors in the EGFR/PI3K/AKT pathway for the survival outcome of oral cancer patients. Cancer Research. 73: 2390-2390. DOI: 10.1158/1538-7445.Am2013-2390  0.466
2012 Feng H, Hu B, Jarzynka MJ, Li Y, Keezer S, Johns TG, Tang CK, Hamilton RL, Vuori K, Nishikawa R, Sarkaria JN, Fenton T, Cheng T, Furnari FB, Cavenee WK, et al. Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America. 109: 3018-23. PMID 22323579 DOI: 10.1073/Pnas.1121457109  0.349
2011 Su H, Sobrino Najul EJ, Toth TA, Ng CM, Lelievre SA, Fred M, Tang CK. Chemokine receptor CXCR4-mediated transformation of mammary epithelial cells by enhancing multiple RTKs expression and deregulation of the p53/MDM2 axis. Cancer Letters. 307: 132-40. PMID 21530075 DOI: 10.1016/J.Canlet.2011.03.025  0.654
2011 Rahimi M, Toth TA, Tang CK. CXCR4 suppression attenuates EGFRvIII-mediated invasion and induces p38 MAPK-dependent protein trafficking and degradation of EGFRvIII in breast cancer cells. Cancer Letters. 306: 43-51. PMID 21454012 DOI: 10.1016/J.Canlet.2011.02.024  0.724
2010 Rahimi M, Huang KL, Tang CK. 3,3'-Diindolylmethane (DIM) inhibits the growth and invasion of drug-resistant human cancer cells expressing EGFR mutants. Cancer Letters. 295: 59-68. PMID 20299148 DOI: 10.1016/J.Canlet.2010.02.014  0.679
2010 Rahimi M, George J, Tang C. EGFR variant-mediated invasion by enhanced CXCR4 expression through transcriptional and post-translational mechanisms. International Journal of Cancer. 126: 1850-60. PMID 19830694 DOI: 10.1002/Ijc.24964  0.708
2009 Zhang Y, Su H, Rahimi M, Tochihara R, Tang C. EGFRvIII-induced estrogen-independence, tamoxifen-resistance phenotype correlates with PgR expression and modulation of apoptotic molecules in breast cancer. International Journal of Cancer. 125: 2021-8. PMID 19588487 DOI: 10.1002/Ijc.24540  0.715
2009 O'Malley S, Su H, Zhang T, Ng C, Ge H, Tang CK. TOB suppresses breast cancer tumorigenesis. International Journal of Cancer. 125: 1805-13. PMID 19569230 DOI: 10.1002/Ijc.24490  0.725
2008 Yu H, Gong X, Luo X, Han W, Hong G, Singh B, Tang CK. Co-expression of EGFRvIII with ErbB-2 enhances tumorigenesis: EGFRvIII mediated constitutively activated and sustained signaling pathways, whereas EGF-induced a transient effect on EGFR-mediated signaling pathways. Cancer Biology & Therapy. 7: 1818-28. PMID 18787418  0.677
2006 Han W, Zhang T, Yu H, Foulke JG, Tang CK. Hypophosphorylation of residue Y1045 leads to defective downregulation of EGFRvIII. Cancer Biology & Therapy. 5: 1361-8. PMID 16969069  0.346
2004 Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Research. 64: 4931-41. PMID 15256466 DOI: 10.1158/0008-5472.Can-03-3681  0.423
2003 Luo X, Gong X, Tang CK. Suppression of EGFRvIII-mediated proliferation and tumorigenesis of breast cancer cells by ribozyme. International Journal of Cancer. 104: 716-21. PMID 12640678 DOI: 10.1002/Ijc.11007  0.748
2003 Tsai MS, Shamon-Taylor LA, Mehmi I, Tang CK, Lupu R. Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer. Oncogene. 22: 761-8. PMID 12569369 DOI: 10.1038/sj.onc.1206130  0.729
2003 Atlas E, Cardillo M, Mehmi I, Zahedkargaran H, Tang C, Lupu R. Heregulin is sufficient for the promotion of tumorigenicity and metastasis of breast cancer cells in vivo. Molecular Cancer Research : McR. 1: 165-75. PMID 12556556  0.613
2002 Ge H, Gong X, Tang CK. Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis. International Journal of Cancer. 98: 357-61. PMID 11920586 DOI: 10.1002/Ijc.10224  0.699
2002 Tang CK. 18 Role of epidermal growth factor receptor in breast carcinoma Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas. 1: 415-424. DOI: 10.1016/S1874-5784(04)80052-7  0.459
2000 Hijazi MM, Thompson EW, Tang C, Coopman P, Torri JA, Yang D, Mueller SC, Lupu R. Heregulin regulates the actin cytoskeleton and promotes invasive properties in breast cancer cell lines. International Journal of Oncology. 17: 629-41. PMID 10995872 DOI: 10.3892/IJO.17.4.629  0.716
2000 Kunisue H, Kurebayashi J, Otsuki T, Tang CK, Kurosumi M, Yamamoto S, Tanaka K, Doihara H, Shimizu N, Sonoo H. Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2. British Journal of Cancer. 82: 46-51. PMID 10638965 DOI: 10.1054/bjoc.1999.0875  0.563
1999 Bianco C, Kannan S, De Santis M, Seno M, Tang CK, Martinez-Lacaci I, Kim N, Wallace-Jones B, Lippman ME, Ebert AD, Wechselberger C, Salomon DS. Cripto-1 indirectly stimulates the tyrosine phosphorylation of erb B-4 through a novel receptor. The Journal of Biological Chemistry. 274: 8624-9. PMID 10085099 DOI: 10.1074/JBC.274.13.8624  0.322
1997 Alimandi M, Wang LM, Bottaro D, Lee CC, Kuo A, Frankel M, Fedi P, Tang C, Lippman M, Pierce JH. Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors. The Embo Journal. 16: 5608-17. PMID 9312020 DOI: 10.1093/Emboj/16.18.5608  0.459
Show low-probability matches.